Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023
- 17 December 2024
- journal article
- review article
- Published by Wiley in ChemistrySelect
- Vol. 9 (47)
Abstract
Telomerase (TERT) is a ribonucleoprotein that regulates telomere length and maintains chromosomal integrity. TERT is a widely expressed protein for replicative immortality in most malignant tumours. TERT is a protein produced by cancer cells that prevents telomere shortening by adding telomere sequences beyond the Hayflick limit, allowing them to divide in an uncontrolled manner. Inhibition of the TERT enzyme is a recognised therapy for treating cancer. The basic objective of the review is to collectively represent the current scenario of treating cancer by inhibiting TERT. With a focus on the recently patented TERT inhibitors and clinical trial data released between 2015 and 2023, this review highlights the work relevant to the development of TERT inhibitors. Furthermore, recent advancements in the clinical development of TERT inhibitors, along with prospective new combinations, are also discussed. The use of TERT inhibitors in cancer therapy has been granted with great interest and significant attention by researchers along with a promising outcome in terms of therapeutic value. Several clinical trial applications and their data gave strong evidence of the use of TERT inhibitors for cancer therapy which provided target therapies, vaccine therapies, nucleoside, non‐nucleoside therapies, and so forth with reduced side effects and enhanced potency.Keywords
Funding Information
- Nirma University (NU/Ph.D./Major_Res_Pro/IP‐NU/21–22/1115)
This publication has 68 references indexed in Scilit:
- Designing of target‐specific N ‐substituted tetrahydroquinoline derivatives as potent mTOR inhibitors via integrated structure‐guided computational approachesChemistrySelect, 2024
- Natural coumarins from two cultivars of watermelon seeds as biosafe anticancer agents, an algorithm for their isolation and evaluationJournal of Molecular Structure, 2023
- Harmful Free Radicals in Aging: A Narrative Review of Their Detrimental Effects on HealthIndian Journal of Clinical Biochemistry, 2023
- Telomerase: A prominent oncological target for development of chemotherapeutic agentsEuropean Journal of Medicinal Chemistry, 2023
- Molecular modelling of quinoline derivatives as telomerase inhibitors through 3D-QSAR, molecular dynamics simulation, and molecular docking techniquesJournal of Molecular Modeling, 2021
- Administration of a Nucleoside Analog Promotes Cancer Cell Death in a Telomerase-Dependent MannerCell Reports, 2018
- Telomere Length and Risk of Cancer and Non-neoplastic Diseases: Is Survivin the Ariadne's Thread?—ReplyJAMA Oncology, 2017
- Long Noncoding RNAs in Cancer PathwaysCancer Cell, 2016
- Telomerase and the search for the end of cancerTrends in Molecular Medicine, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011